Thermo Fisher Scientific (NYSE:TMO) is set to announce its earnings results before the market opens on Wednesday, January 31st. Analysts expect the company to announce earnings of $2.67 per share for the quarter.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the previous year, the company posted $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, analysts expect Thermo Fisher Scientific to post $9 EPS for the current fiscal year and $11 EPS for the next fiscal year.
Shares of Thermo Fisher Scientific (NYSE:TMO) opened at $214.55 on Wednesday. Thermo Fisher Scientific has a fifty-two week low of $140.00 and a fifty-two week high of $217.22. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $85,580.00, a PE ratio of 36.43, a price-to-earnings-growth ratio of 1.74 and a beta of 1.06.
In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the transaction, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.49% of the company’s stock.
An institutional investor recently raised its position in Thermo Fisher Scientific stock. Ark Investment Management LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,005 shares of the medical research company’s stock after purchasing an additional 488 shares during the period. Ark Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $3,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 86.22% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have issued reports on TMO shares. Goldman Sachs Group started coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target for the company. Jefferies Group reissued a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Leerink Swann upped their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Finally, Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average price target of $212.21.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.